Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2340/00015555-1889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sirolimus Induced Toxic Optic Neuropathy.
Int Med Case Rep J
May 2023
Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
Objective: To describe a case of optic neuropathy after prolonged sirolimus therapy in the setting of cardiac transplant.
Background: Sirolimus is an immunosuppressant that inhibits Mechanistic Target of Rapamycin (mTOR) and blocks T-cell activation and B-cell differentiation by preventing response to Interleukin-2 (IL-2). Tacrolimus is another immunosuppressive agent, one of the known but uncommon side effects of which is bilateral optic neuropathy years after taking the medication.
Intestinal Dysbiosis Correlates With Sirolimus-induced Metabolic Disorders in Mice.
Transplantation
May 2021
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Background: Long-time use of pharmacological immunosuppressive agents frequently leads to metabolic disorders. Most studies have focused on islet toxicity leading to posttransplantation diabetes mellitus. In contrast, the link between intestinal dysbiosis and immunosuppressive drug-induced metabolic disorders remains unclear.
View Article and Find Full Text PDFSirolimus-induced inflammatory lymphoedema of the breast resolved after switching to cyclosporine.
Acta Derm Venereol
January 2015
Department of Dermatology, CHRU de Tours, FR-37044 Tours, France.
Profiling sirolimus-induced inflammatory syndrome: a prospective tricentric observational study.
PLoS One
July 2013
Service de Transplantation, néphrologie et Immunologie Clinique de l'Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France ; Université de Lyon, Lyon, France.
Background: The use of the immunosuppressant sirolimus in kidney transplantation has been made problematic by the frequent occurrence of various side effects, including paradoxical inflammatory manifestations, the pathophysiology of which has remained elusive.
Methods: 30 kidney transplant recipients that required a switch from calcineurin inhibitor to sirolimus-based immunosuppression, were prospectively followed for 3 months. Inflammatory symptoms were quantified by the patients using visual analogue scales and serum samples were collected before, 15, 30, and 90 days after the switch.
Coronary aneurysm associated with coronary perforation after sirolimus-eluting stents implantation: close follow-up exceeding 2 years by coronary 3-dimensional computed tomography.
J Cardiol
August 2009
Department of Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.
Both coronary perforation and aneurysms associated with sirolimus-eluting stent (SES) implantations are uncommon complications. We describe an unusual case of a coronary aneurysm associated with a coronary perforation after SES implantation. Although their pathogenesis has not yet been completely elucidated, some technical factors including the use of excessive pressure during the stent deployment, and sirolimus-induced vascular inflammatory reactions and poor healing response at the perforation site may be related to the shape of the aneurismal formation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!